Breaking News

Piramal’s Mumbai Facility Gains Indian GLP Certification

By Kristin Brooks | March 27, 2014

Areas of toxicity, mutagenicity, analytical and clinical chemistry testing in compliance

Piramal Enterprises Ltd.’s R&D facility in Goregaon, Mumbai, has received GLP Compliance Certification from the National GLP Compliance Monitoring Authority (NGCMA), Government of India. The certification covered areas of toxicity, mutagenicity, analytical and clinical chemistry testing, as well as hERG, bioanalysis and toxicokinetic evaluation.
 
The Goregaon facility provides drug discovery and development of New Chemical Entities (NCE) in the area of oncology and metabolic disorders.
 
Dr. Owe Owar, president of NCE Research, Piramal Enterprisessaid, "The GLP certification is a testament to high quality research through thorough SOP-driven Good Laboratory Practices, competent well-trained personnel and systematic documentation at Piramal's NCE R&D facility in Mumbai. Piramal's NCE R&D unit is committed to realize its mission towards serving patients globally with medicines that matter."

Related Compliance:

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Biopharma CMO Market Trends

    Biopharma CMO Market Trends

    Tim Wright, Editor||June 2, 2016
    Continued strong growth in biopharma industry is being driven by biosimilars